Status:
ACTIVE_NOT_RECRUITING
A Clinical Study of MK-1084 With Rosuvastatin and Metformin in Healthy People (MK-1084-016)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
19-60 years
Phase:
PHASE1
Brief Summary
Researchers want to learn about MK-1084 when given with rosuvastatin and metformin in healthy people. The goal of this study is to compare the amount of rosuvastatin and metformin in a person's body o...
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to the following:
- \- Has body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2
Exclusion
- The main exclusion criteria include but are not limited to the following:
- Has history of cancer (malignancy)
- Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
Key Trial Info
Start Date :
November 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 23 2025
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT07222098
Start Date
November 19 2025
End Date
December 23 2025
Last Update
December 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion ( Site 0001)
Lincoln, Nebraska, United States, 68502